Literature DB >> 34606112

Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy.

V Schmidt1,2, R Blum3, M Möhrenschlager1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34606112     DOI： 10.1111/jdv.17722

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  4 in total

1.  Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study.

Authors:  Carlo Alberto Maronese; Marzia Caproni; Chiara Moltrasio; Giovanni Genovese; Pamela Vezzoli; Paolo Sena; Giulia Previtali; Emanuele Cozzani; Giulia Gasparini; Aurora Parodi; Laura Atzori; Emiliano Antiga; Roberto Maglie; Francesco Moro; Elena Biancamaria Mariotti; Alberto Corrà; Sabatino Pallotta; Biagio Didona; Angelo Valerio Marzano; Giovanni Di Zenzo
Journal:  Front Med (Lausanne)       Date:  2022-02-28

2.  Reply to "New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin".

Authors:  Carlo Alberto Maronese; Giovanni Di Zenzo; Giovanni Genovese; Francesca Barei; Alice Monestier; Anna Pira; Chiara Moltrasio; Angelo Valerio Marzano
Journal:  Dermatol Ther       Date:  2022-04-10       Impact factor: 3.858

Review 3.  Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.

Authors:  Yhojan Rodríguez; Manuel Rojas; Santiago Beltrán; Fernando Polo; Laura Camacho-Domínguez; Samuel David Morales; M Eric Gershwin; Juan-Manuel Anaya
Journal:  J Autoimmun       Date:  2022-08-24       Impact factor: 14.511

Review 4.  Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.

Authors:  Elena Calabria; Federica Canfora; Massimo Mascolo; Silvia Varricchio; Michele Davide Mignogna; Daniela Adamo
Journal:  Pathol Res Pract       Date:  2022-03-05       Impact factor: 3.309
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.